Twice-Daily Triple Nucleoside Intensification Treatment with Lamivudine-Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET Study

This open-label, multicenter, single-arm clinical trial assessed the 48-week efficacy of a twice-daily triple nucleoside reverse-transcriptase inhibitor regimen containing a lamivudine (150 mg)—zidovudine (300 mg) combination tablet (COM) and abacavir (ABC; 300 mg) in 87 antiretroviral therapy-exper...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2001-02, Vol.183 (4), p.571-578
Hauptverfasser:	Henry, Keith, Wallace, Robert J., Bellman, Paul C., Norris, Dorece, Fisher, Robin L., Ross, Lisa L., Liao, Qiming, Shaefer, Mark S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretrovirals Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Clinical trials Codons Dideoxynucleosides - administration & dosage Dideoxynucleosides - therapeutic use Drug Therapy, Combination Female Genetic mutation HIV HIV 1 HIV Infections - drug therapy HIV Infections - virology HIV-1 - genetics HIV-1 - physiology Human viral diseases Humans Infectious diseases Lamivudine - administration & dosage Lamivudine - therapeutic use Major Articles Male Medical sciences Middle Aged Nucleosides Pharmacology. Drug treatments Reverse Transcriptase Inhibitors - therapeutic use RNA RNA, Viral - blood Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Virology Viruses Zidovudine - administration & dosage Zidovudine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!